Saturday, 21 April 2018 - 4:44
  • it
  • de
  • en
  • fr

Aimmune Therapeutics

Aimmune’s peanut allergy drug successful

US-based biotech Aimmune Therapeutics yesterday announced positive clinical results from its Phase-III Parisade clinical trial enrolling 554 patients with peanut allergy, treated with the AR101 investigational therapy. The results have demonstrated that 2/3 of the patients better tolerate at least…

Nestlé invests in Aimmune Therapeutics ($145m)

Switzerland-based multinational Nestlé has invested $145m in shares of Aimmune Therapeutics, Inc. by means of its subsidiary Nestlé Health Science. Aimmune is a biopharmaceutical company developing a novel therapeutic approach to food allergies. Its most promising investigational product is AR101,…